Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2024 · 92 positions · Total reported value $1.13B · Top-10 concentration 36.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2024 13F filing, Soleus Capital Management, L.P. disclosed 92 equity positions with a combined reported value of $1.13B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 36.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were TGTX ($64.85M), IOVA ($60.53M), UTHR ($45.07M). By sector, the heaviest allocations are Health Care 78.4%, Industrials 1.2%. Versus the prior quarter, allocation shifted toward Health Care (+9.5pp), Industrials (+1.2pp) and away from Materials (-0.6pp), Other (-10.1pp).

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q2 2024 were TERN ($33.69M), ELVN ($17.98M), ALNY ($17.42M).

Of the 27 positions fully exited versus the prior quarter, the largest were XBI ($208.76M), HCA ($17.16M), BIIB ($15.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • TERN TERNS PHARMACEUTICALS INC · $33.69M
  • ELVN ENLIVEN THERAPEUTICS INC · $17.98M
  • ALNY ALNYLAM PHARMACEUTICALS INC · $17.42M
  • TXG 10X GENOMICS INC · $13.98M
  • ALEC ALECTOR INC · $10.17M
  • BDSX BIODESIX INC · $9.35M
  • KIDS ORTHOPEDIATRICS CORP · $8.90M
  • AVDL AVADEL PHARMACEUTICALS · $7.16M

Fully Exited (vs previous quarter)

  • XBI SPDR SERIES TRUST · prev qtr: $208.76M
  • HCA HCA HEALTHCARE INC · prev qtr: $17.16M
  • BIIB BIOGEN INC · prev qtr: $15.70M
  • MNKD MANNKIND CORP · prev qtr: $7.06M
  • MNMD MIND MEDICINE MINDMED INC · prev qtr: $7.05M
  • VKTX VIKING THERAPEUTICS INC · prev qtr: $5.50M
  • CMPS COMPASS PATHWAYS PLC · prev qtr: $4.71M
  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $4.58M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.4%
Materials 0.5%
Other 19.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.65M $64.85M 5.72%
5.72%
Add
2 7.55M $60.53M 5.34%
5.34%
Add
3 141.50K $45.07M 3.98%
3.98%
Reduce
4 2.06M $42.91M 3.78%
3.78%
Add
5 7.29M $39.68M 3.50%
3.50%
Add
6 4.95M $33.69M 2.97%
2.97%
New
7 856.18K $33.23M 2.93%
2.93%
Add
8 781.78K $32.87M 2.90%
2.90%
Reduce
9 11.52M $32.25M 2.84%
2.84%
Add
10 1.28M $28.97M 2.56%
2.56%
Add
11 694.07K $24.37M 2.15%
2.15%
Add
12 3.31M $23.93M 2.11%
2.11%
Add
13 126.00K $23.14M 2.04%
2.04%
Add
14 376.32K $22.27M 1.96%
1.96%
Add
15 123.45K $22.22M 1.96%
1.96%
Add
16 4.21M $22.15M 1.95%
1.95%
Add
17 533.01K $22.05M 1.94%
1.94%
Add
18 1.21M $19.84M 1.75%
1.75%
Reduce
19 408.37K $19.66M 1.73%
1.73%
Add
20 137.70K $19.65M 1.73%
1.73%
Reduce
21 4.05M $18.72M 1.65%
1.65%
Add
22 853.63K $18.58M 1.64%
1.64%
Add
23 2.43M $18.39M 1.62%
1.62%
Hold
24 769.26K $17.98M 1.58%
1.58%
New
25 71.70K $17.42M 1.54%
1.54%
New
26 826.50K $16.97M 1.50%
1.50%
Add
27 44.36K $16.57M 1.46%
1.46%
Reduce
28 415.00K $15.98M 1.41%
1.41%
Add
29 2.37M $15.73M 1.39%
1.39%
Add
30 185.25K $13.99M 1.23%
1.23%
Reduce
31 719.00K $13.98M 1.23%
1.23%
New
32 424.58K $13.40M 1.18%
1.18%
Add
33 171.79K $13.03M 1.15%
1.15%
Add
34 1.15M $12.50M 1.10%
1.10%
Add
35 799.55K $10.37M 0.92%
0.92%
Add
36 2.24M $10.17M 0.90%
0.90%
New
37 221.60K $10.13M 0.89%
0.89%
Reduce
38 586.50K $9.53M 0.84%
0.84%
Reduce
39 170.74K $9.42M 0.83%
0.83%
Add
40 6.11M $9.35M 0.82%
0.82%
New
41 1.05M $9.01M 0.79%
0.79%
Reduce
42 309.50K $8.90M 0.79%
0.79%
New
43 1.04M $8.58M 0.76%
0.76%
Reduce
44 1.21M $8.41M 0.74%
0.74%
Add
45 7.29M $8.10M 0.71%
0.71%
Hold
46 647.98K $7.83M 0.69%
0.69%
Add
47 800.00K $7.54M 0.67%
0.67%
Hold
48 399.43K $7.51M 0.66%
0.66%
Reduce
49 509.00K $7.16M 0.63%
0.63%
New
50 201.00K $7.09M 0.63%
0.63%
New

FAQ

What did Soleus Capital Management, L.P. buy in 2024-Q2?

In its 2024-Q2 13F filing, Soleus Capital Management, L.P. reported 92 equity positions worth $1.13B in aggregate; its largest disclosed positions were TGTX ($64.85M), IOVA ($60.53M), UTHR ($45.07M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $1.13B of long equity holdings across 92 positions as of 2024-Q2. Top-10 holdings account for 36.5% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →